Chemotherapy Before Surgery (Neoadjuvant): Why & When

Disclaimer: This article provides general educational information about neoadjuvant chemotherapy. Treatment decisions are highly individual and depend on the cancer type, stage, and patient health. Always discuss your specific treatment plan with your oncology team. This does not replace a medical consultation.

The approach

Chemotherapy first, surgery second

Main goals

Shrink tumour, treat hidden cells

Best outcome

Easier, safer, more complete surgery

1 What is neoadjuvant therapy?

"Neoadjuvant" simply means "given before the main treatment". In cancer care, the main treatment is usually surgery — so neoadjuvant therapy refers to any treatment given before the operation. This most commonly means chemotherapy, but it may also include radiation therapy (neoadjuvant chemoradiation), targeted therapy, or immunotherapy depending on the cancer type.

The idea is straightforward: rather than removing the cancer first and then giving chemotherapy to clean up afterwards, doctors give the chemotherapy first — to weaken the cancer, shrink it, and treat any cells that may have already escaped the primary tumour but are too small to see on scans.

Traditional approach

Surgery first → chemotherapy afterwards (called adjuvant chemotherapy)

• Tumour removed at full size
• No information on drug response before surgery
• Recovery from surgery may delay or limit chemo

Neoadjuvant approach

Chemotherapy first → then surgery (and sometimes more treatment afterwards)

• Tumour is smaller and easier to remove
• Doctors can see how the cancer responds
• Hidden cancer cells treated earlier

A quick vocabulary note: Neoadjuvant = before main treatment. Adjuvant = after main treatment. Perioperative = both before and after. Many modern protocols are actually perioperative — chemotherapy is given before surgery, and then resumed after recovery.

2 Why give chemotherapy before surgery?

The case for neoadjuvant chemotherapy rests on five distinct benefits. Each on its own would be a reason to consider it; together, they explain why this approach has become standard for so many cancers.

The principle

By the time most cancers are diagnosed, microscopic cells may have already travelled beyond the visible tumour. Treating those cells early — before surgery — addresses the cancer as a whole-body problem, not just a local one.

Shrinks the tumour (downstaging)

A smaller tumour is easier to remove cleanly. Surgeons can achieve clear margins more often, may be able to spare more healthy tissue, and may convert a borderline operable tumour into one that can be safely resected. In some cases, downstaging makes the difference between an operation being possible and not possible at all.

Treats microscopic cancer cells early

Even when scans look clean elsewhere in the body, some cancer cells may have already broken away from the primary tumour. These cells are too small to see but they are the reason cancers can recur years after a successful operation. Neoadjuvant chemotherapy hits these cells while they are still few in number — often when treatment works best.

Tests how the cancer responds

Once chemotherapy is given, doctors can see — on scans, and later on the removed surgical specimen — exactly how much the cancer has responded. This is uniquely valuable: it confirms whether the chosen drugs are working, and helps guide treatment decisions after surgery. If the response is excellent, the team has high confidence in continuing the same drugs; if poor, the strategy can be changed.

Enables organ or function preservation

In some cancers — breast, rectal, bladder, and head and neck cancers especially — shrinking the tumour before surgery can mean a smaller, more conservative operation. That may translate to preserving the breast, avoiding a permanent stoma, or keeping more function intact. The patient's quality of life after treatment can be meaningfully better.

Ensures treatment is actually delivered

Patients tolerate chemotherapy better before surgery than after. Recovery from a major cancer operation can delay or even prevent the full course of post-surgery chemotherapy, especially in older patients. Giving it upfront ensures the systemic part of the treatment is completed when the patient is strongest.

3 Which cancers benefit from neoadjuvant chemotherapy?

Neoadjuvant therapy is now standard or commonly used for several cancers, particularly when the disease is locally advanced — meaning the tumour is larger or has involved nearby lymph nodes, but has not spread to distant organs. The specific regimen depends on the cancer type and the patient's overall health.

Esophageal cancer

Neoadjuvant chemoradiation (CROSS protocol) or chemotherapy alone is now standard for locally advanced disease. It significantly improves the chance of complete surgical removal and long-term survival.

Stomach (gastric) cancer

Perioperative chemotherapy — typically the FLOT regimen — has become standard for resectable stomach cancers, replacing surgery-first approaches in much of the world.

Breast cancer

Commonly used in larger, HER2-positive, or triple-negative tumours. Often enables breast-conserving surgery instead of mastectomy.

Rectal cancer

Chemotherapy combined with radiation is standard for locally advanced rectal cancer. May allow sphincter preservation and avoid a permanent stoma.

Bladder cancer

Cisplatin-based chemotherapy before cystectomy improves survival in muscle-invasive disease and is now considered standard care.

Non-small cell lung cancer

Used in selected stage II–III cases, increasingly combined with immunotherapy. The treatment landscape here is evolving rapidly.

Pancreatic cancer

Used particularly for borderline-resectable tumours. May convert an inoperable cancer into one suitable for surgery.

Soft tissue & bone sarcomas

Selected sarcomas, particularly osteosarcoma and Ewing's sarcoma, are routinely treated with chemotherapy before surgical removal.

Important: Not every patient with these cancers needs neoadjuvant chemotherapy. The decision depends on tumour stage, location, biology, and the patient's overall health — and should be made at a multidisciplinary tumour board, where surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists review the case together.

4 What to expect: the typical timeline

The complete treatment journey usually takes 3 to 5 months from the start of chemotherapy to surgery, with further treatment often continuing afterwards. Here is the typical sequence.

Diagnosis & staging

~1–2 weeks

Biopsy confirms the diagnosis. Scans (CT, PET-CT, MRI as needed) and endoscopy determine the stage. A multidisciplinary tumour board reviews the case and recommends the treatment plan.

Pre-treatment workup

~1 week

Blood tests, heart function tests (echo or ECG), nutritional assessment, and a port (central line) insertion if needed. Patients are counselled on what to expect.

Neoadjuvant chemotherapy

~2–4 months

Chemotherapy is given in cycles, usually every 2 to 3 weeks. Each cycle includes drug administration plus a recovery period. Blood tests are done before each cycle to confirm the patient is well enough to continue.

Restaging

~1–2 weeks after last cycle

New scans assess how the cancer has responded. The team confirms whether surgery is still the right next step or whether the plan needs adjustment.

Surgery

~4–8 weeks after last chemotherapy cycle

The body needs time to recover from chemotherapy before surgery — usually a 4 to 6 week gap. The tumour is then removed, often together with regional lymph nodes.

Pathology & further treatment

2–6 weeks after surgery

The removed tissue is analysed to confirm the response to chemotherapy. Based on this, further chemotherapy, radiation, or immunotherapy may be recommended.

5 How doctors assess response to chemotherapy

One of the unique advantages of giving chemotherapy before surgery is that the team can directly measure how well it is working. Response is assessed in two stages: on scans before surgery, and on the actual tissue after it is removed.

The four response categories

✓

Complete response (pCR)

No cancer cells visible in the removed specimen. This is the best possible response and is strongly associated with improved long-term survival.

↓

Major response

Most of the tumour has been destroyed, with only small areas of cancer remaining. Strong indicator that the chemotherapy was effective.

Partial response

The tumour has shrunk meaningfully but significant cancer remains. The treatment plan after surgery may be intensified.

Poor or no response

Limited or no shrinkage. The chemotherapy regimen may be changed, radiation may be added, or the post-surgery treatment plan revised.

Why this matters: The response to neoadjuvant chemotherapy is one of the strongest predictors of long-term outcome — often more important than the original stage at diagnosis. It tells the team not just what was true at the start, but what the cancer is actually doing now.

6 Side effects & how they are managed

Side effects vary depending on the specific drugs used, the dose, and the individual. Many patients are surprised to find that with modern supportive care, chemotherapy is more manageable than they had feared. Most side effects are temporary and resolve after treatment ends.

Fatigue

The most common side effect. Usually worse in the first few days after each cycle and improves between cycles. Light activity helps.

Nausea & appetite changes

Modern anti-nausea medications are highly effective. Most patients no longer experience the severe nausea associated with chemotherapy in the past.

Low blood counts

Reduced white cells (infection risk), red cells (anaemia), or platelets (bleeding risk). Monitored with blood tests before each cycle.

Tingling in hands & feet

Some drugs cause peripheral neuropathy. Usually mild and reversible, but dose adjustments can be made if it becomes troublesome.

Hair loss

Depends on the drug — not all chemotherapy causes hair loss. When it occurs, hair almost always regrows after treatment ends.

Mouth sores

Manageable with mouth rinses and dietary adjustments. Good oral hygiene before and during treatment helps prevent them.

When to contact your oncology team urgently

! Fever above 38°C (100.4°F)

! Persistent vomiting or inability to keep fluids down

! Severe diarrhoea

! Unusual bleeding or bruising

! Breathing difficulty or chest pain

! Any new or worsening symptom that concerns you

7 Preparing well for treatment

How a patient enters treatment matters. Patients who arrive well-nourished, physically active, and well-supported tolerate chemotherapy better, recover from surgery faster, and have better long-term outcomes. The pre-treatment period — even a few weeks — is an opportunity to build that foundation.

Practical preparation checklist

✓ Eat a protein-rich, balanced diet to support healing

✓ Stay physically active — walking is excellent

✓ Stop smoking — this single change improves outcomes significantly

✓ Limit alcohol during treatment

✓ Complete any dental work before chemotherapy starts

✓ Get vaccinations recommended by your team beforehand

✓ Arrange a caregiver or family support during cycles

✓ Maintain regular sleep and stress management

✓ Bring a list of all medications and supplements to consultations

✓ Ask questions — there are no small ones

The bottom line: Neoadjuvant chemotherapy is not a setback or a delay — it is part of giving the cancer the strongest possible response. Patients who understand the plan, stay engaged with their team, and prepare well consistently do better.

Key takeaways

✓ Neoadjuvant chemotherapy is given before surgery to shrink the tumour and treat hidden cancer cells.

✓ It is now standard care for esophageal, gastric, breast, rectal, and bladder cancer — among others.

✓ Surgery becomes easier and more likely to be successful when the tumour has been downstaged.

✓ Treatment response is itself one of the strongest predictors of long-term outcome.

✓ Side effects are usually manageable with modern supportive care — most resolve after treatment.

✓ Treatment decisions should be made at a multidisciplinary tumour board, not by one specialist alone.

Frequently asked questions

What is neoadjuvant chemotherapy?

Neoadjuvant chemotherapy is chemotherapy given before the main treatment — usually surgery. The goal is to shrink the tumour, treat any microscopic cancer cells that may have spread, and improve the chances of a complete surgical removal. It is now standard practice for several cancers, including esophageal, stomach, breast, rectal, and bladder cancer.

Why give chemotherapy before surgery instead of after?

Giving chemotherapy first offers several advantages: it shrinks the tumour so surgery is easier and safer, treats microscopic cancer cells that may have already spread elsewhere, allows doctors to see how the cancer responds to that specific drug combination, and may help preserve organs or function. In many cancers, this approach has been shown to improve long-term survival compared with surgery alone.

Which cancers commonly use neoadjuvant chemotherapy?

Neoadjuvant chemotherapy is now standard or commonly used for: locally advanced esophageal cancer, gastric (stomach) cancer, breast cancer (especially larger or aggressive tumours), rectal cancer, bladder cancer, certain non-small cell lung cancers, pancreatic cancer (in selected cases), and some sarcomas. Your oncology team will decide based on the tumour type, stage, location, and your overall health.

How long does neoadjuvant chemotherapy take?

Most neoadjuvant regimens last 2 to 4 months, given as cycles every 2 to 3 weeks. After completion, there is usually a 4 to 8 week gap before surgery, during which restaging scans are performed to assess response. The total timeline from starting chemotherapy to surgery is typically 3 to 5 months.

What are the side effects of neoadjuvant chemotherapy?

Common side effects include fatigue, nausea, hair loss, reduced appetite, mouth sores, low blood counts (which can increase infection risk), and nerve-related symptoms like tingling in hands and feet. Most side effects are temporary and manageable with supportive care. Modern anti-nausea medications and supportive treatments have substantially improved tolerability compared with chemotherapy in earlier decades.

What happens if the tumour does not shrink with chemotherapy?

Not every tumour shrinks with chemotherapy, and that information itself is valuable. If response is poor, the team may switch to a different drug regimen, add radiation therapy, or proceed directly to surgery. A poor response does not necessarily mean a poor outcome — it simply means the strategy needs to be adjusted, which is one of the reasons treatment is planned by a multidisciplinary tumour board.

Please consult a qualified oncology team if you or a loved one is being considered for chemotherapy before surgery.

WhatsApp X LinkedIn